|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
1999-9-23
|
|
pubmed:abstractText |
A series of arylpiperazine derivatives were prepared and evaluated for their alpha1-adrenoceptor antagonistic activities and 5alpha-reductase inhibitory activities. SAR study led to the identification of the potent dual-acting compound 2f, which had a pA2 value of 7.5 for alpha1-adrenoceptor antagonism and an IC50 value of 1.5 nM for 5alpha-reductase inhibition.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
7
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1553-8
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10386934-Adrenergic alpha-Antagonists,
pubmed-meshheading:10386934-Animals,
pubmed-meshheading:10386934-Cholestenone 5 alpha-Reductase,
pubmed-meshheading:10386934-Dose-Response Relationship, Drug,
pubmed-meshheading:10386934-Inhibitory Concentration 50,
pubmed-meshheading:10386934-Male,
pubmed-meshheading:10386934-Models, Chemical,
pubmed-meshheading:10386934-Oxidoreductases,
pubmed-meshheading:10386934-Piperazines,
pubmed-meshheading:10386934-Prostate,
pubmed-meshheading:10386934-Rabbits,
pubmed-meshheading:10386934-Rats,
pubmed-meshheading:10386934-Rats, Sprague-Dawley
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Dual-acting agents with alpha1-adrenoceptor antagonistic and steroid 5alpha-reductase inhibitory activities. Synthesis and evaluation of arylpiperazine derivatives.
|
|
pubmed:affiliation |
Central Research Laboratories, Zeria Pharmaceutical Co., Ltd., Saitama, Japan.
|
|
pubmed:publicationType |
Journal Article
|
